Dr Patrick Brown speaks to ecancer at the ASH 2019 meeting in Orlando about follow up results of the addition of lestaurtinib to chemotherapy in infants with acute lymphoblastic leukaemia (ALL).
He explains that, while previous research indicated that the addition of lestaurtinib to chemotherapy did not improve outcomes, they wanted to find markers that may indicate sensitivity to FLT3 inhibition.
Dr Brown reports that two markers were identified in a small proportion of patients who had improved outcomes from the addition of lestaurtinib to chemotherapy.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content